Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Beigene Ltd Ads (NQ: BGNE)
124.74 USD  +0.63 (+0.51%)
Official Closing Price  /  Updated: 4:36 PM EDT, Oct 19, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 357,200
Open 125.27
Bid (Size) 124.71 (6)
Ask (Size) 124.78 (5)
Prev. Close 124.11
Today's Range 124.29 - 129.05
52wk Range 77.54 - 220.10
Shares Outstanding 53,760,296
Dividend Yield N/A
Performance
YTD
+23.74%
+23.74%
1 Month
-23.71%
-23.71%
3 Month
-26.29%
-26.29%
6 Month
-25.75%
-25.75%
1 Year
+48.09%
+48.09%
Top News
More News
Detailed Research: Economic Perspectives on BeiGene, Costco Wholesale, Rogers, Advance Auto Parts, Celcuity, and Harris — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of BeiGene, Ltd.... Read More
from GlobeNewswire News Releases
BeiGene Announces Updated Results from Phase 1 Clinical Trial of Zanubrutinib in Patients with Waldenström’s Macroglobulinemia
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the... Read More
from GlobeNewswire News Releases
More News
Read More
MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies
from PR Newswire
BeiGene Announces National Reimbursement Inclusion of VIDAZA® (Azacitidine for Injection) by the State Medical Insurance Administration in China
from GlobeNewswire News Releases
BeiGene to Present Clinical Data on Zanubrutinib and Pamiparib at Upcoming Medical Meetings
from GlobeNewswire News Releases
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
from GlobeNewswire News Releases
BeiGene to Present at Upcoming Investor Conferences
from GlobeNewswire News Releases
BeiGene Announces Preliminary Results from the Phase 1 Clinical Trial of Zanubrutinib in Chinese Patients with B-Cell Lymphoma at Annual Meeting of the Chinese Society of Clinical Oncology
from GlobeNewswire News Releases
BeiGene Presents Results on Anti-PD-1 Antibody Tislelizumab in Chinese Patients with Lung Cancers at the Annual Meeting of the Chinese Society of Clinical Oncology
from GlobeNewswire News Releases
BeiGene Presents Preliminary Results on Anti-PD-1 Antibody Tislelizumab in Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors at Annual Meeting of the Chinese Soci
from GlobeNewswire News Releases
BeiGene Announces Oral Data Presentations at Annual Meeting of the Chinese Society of Clinical Oncology
from GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.